comparative effectiveness

Guideline-Recommended Therapy Underused in Rare Form of Bladder Cancer

05/16/2017

JCP Editors

Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma (MPBC) is often foregone in community cancer centers and academic centers, according to a study presented at the American...

...

05/16/2017

Journal of Clinical Pathways

Research in Review

Biomarker-Driven Treatment Does Not Improve NSCLC Outcomes

05/15/2017

JCP Editors

Selecting patients with cyclooxygenase-2 (COX-2) expression by immunohistochemistry fails to improve survival outcomes in non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical...

...

05/15/2017

Journal of Clinical Pathways

Research in Review

Lenalidomide Maintenance Prolongs PFS in Older Patients With Diffuse B-Cell Lymphoma

05/12/2017

JCP Editors

Lenalidomide maintenance therapy for 24 months after obtaining a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large...

...

05/12/2017

Journal of Clinical Pathways

Research in Review

Surveillance More Effective Than Surgery for Patients With Rectal Cancer After First-Line Care

05/09/2017

JCP Editors

Patients with rectal cancer who undergo first-line chemotherapy and radiation have lower risk of recurrence and higher rates of survival regardless of whether they choose to have surgery, according to a study...

...

05/09/2017

Journal of Clinical Pathways

Research in Review

Patients With NSCLC Treated With Immunotherapy Likely to Respond to Chemo

05/09/2017

JCP Editors

Patients with advanced non-small cell lung cancer (NSCLC) who undergo salvage chemotherapy are 30% more likely to achieve partial response if they have been treated with a PD-1/PD-L1 checkpoint inhibitor, according...

...

05/09/2017

Journal of Clinical Pathways

Research in Review

Older Patients With CLL Have Higher Risk of Disease-Related Mortality

05/04/2017

JCP Editors

Chronic lymphocytic leukemia (CLL)-related mortality is significantly higher in patients aged 75 years or older, prompting a need for novel treatment options, according to a study published in BMC Cancer...

...

05/04/2017

Journal of Clinical Pathways

Research in Review

Lenalidomide Maintenance Prolongs PFS in Older Patients With Diffuse Large B-Cell Lymphoma

04/28/2017

JCP Editors

Lenalidomide maintenance therapy for 24 months after a complete or partial response to standard chemotherapy significantly prolongs progression-free survival (PFS) in older patients with diffuse large B-cell...

...

04/28/2017

Journal of Clinical Pathways

Research in Review

Cost-Effectiveness of Early-Stage Breast Cancer Treatment Options Vary Significantly

04/21/2017

JCP Editors

Certain therapy options for early-stage breast cancer have fewer associated complications and are much less expensive than others, according to a study published in the Journal of the National Cancer Institute...

...

04/21/2017

Journal of Clinical Pathways

Research in Review

Palbociclib Plus Fulvestrant Improves PFS in Type of Breast Cancer

04/19/2017

JCP Editors

Adding palbociclib to fulvestrant prolongs progression-free survival (PFS) compared with fulvestrant alone among pre- and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor...

Adding...

04/19/2017

Journal of Clinical Pathways

Research in Review

Transplantation After High-Dose Chemo Effective in Treating Multiple Myeloma

04/19/2017

JCP Editors

Adult patients with multiple myeloma who receive a high-dose chemotherapy regimen plus autologous stem-cell transplantation improve their median progression-free survival (PFS) by 14 months compared with patients who...

Adult...

04/19/2017

Journal of Clinical Pathways